Clinical trial NCT00671619: Study of ESBA105 Eye Drops in Healthy Subjects
Official title: A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: opthalmology
antibody fragment
TNF alpha
Lead sponsor: ESBATech AG
Sponsor class: INDUSTRY
First posted: 2008-05-05
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Objectives:

To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.

To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.

Detailed description: ESBA105 is an anti TNF single chain antibody fragment

Eligibility criteria: Inclusion Criteria:

* Male or female Caucasian subjects.
* Written informed consent prior to any study procedures including screening tests for eligibility.
* Subjects should be in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
* Normal sitting blood pressure and pulse rate, i.e.: BP: 100-160 mm Hg systolic, 50-90 mm Hg diastolic and pulse rate: 45-100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
* Bilateral corrected visual acuity of at least 0.9
* No need for regular concomitant medication.
* Ability to communicate well with the investigator and comply with the requirements of the entire study.
* Use of qualified contraception

Exclusion Criteria:

* Any evidence of infectious disease as evidenced by medical history, clinical examination, positive serology results which indicate the presence of hepatitis B and/ or C or HIV infection or positive results of the QuantiFERON TB Gold test based latent tuberculosis testing.
* History of serious adverse reactions or hypersensitivity to any drug.
* Presence or history of any allergy including allergic conjunctivitis requiring acute or chronic treatment (seasonal allergic rhinitis not associated to conjunctivitis which requires no treatment may be tolerated).
* Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
* Existence of any surgical or medical condition which might interfere with the evaluation of the general drug safety and tolerability including clinically relevant ophthalmological diseases, impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, haematological abnormalities, psychiatric diseases, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
* Shallow anterior chamber, closed angle glaucoma or any other contraindication to eye dilation for ophthalmological examination.
* History or presence of any other clinically relevant (in the opinion of the Investigator) ocular disease.

Primary outcomes:
measure: safety and tolerability
timeFrame: several timepoints
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Swiss Pharma Contract
Study officials:
References: